Delfi Diagnostics: Amoolya Singh

Amoolya Singh has been named chief technology officer of cancer liquid biopsy firm Delfi Diagnostics. She joins the company from Grail, where she was senior VP of data science and CSO. Prior to that, she was head of discovery technologies at Calico, Alphabet's drug discovery company, and VP of R&D at Amyris. Singh holds a PhD in computational biology and an MS in computer science from the University of California, Berkeley, and a BS in biology and computer science from Carnegie Mellon University. She also completed postdoctoral fellowships at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, and at Emory University and worked as a software engineer at various companies.